Michelina Nascimbeni, Thomas Montange, Helen K. W. Law, Vincent Mallet, Bertrand Saunier, Yves Rivière, Stanislas Pol – 23 December 2009
Ji‐Yuan Zhang, Zheng Zhang, Fang Lin, Zheng‐Sheng Zou, Ruo‐Nan Xu, Lei Jin, Jun‐Liang Fu, Feng Shi, Ming Shi, Hui‐Fen Wang, Fu‐Sheng Wang – 23 December 2009 – Interleukin‐17 (IL‐17)‐producing CD4+ T cells (Th17)‐mediated immune response has been demonstrated to play a critical role in inflammation‐associated disease; however, its role in chronic hepatitis B virus (HBV) infection remains unknown.
Florian van Bömmel, Robert A. de Man, Heiner Wedemeyer, Katja Deterding, Jörg Petersen, Peter Buggisch, Andreas Erhardt, Dietrich Hüppe, Kerstin Stein, Jörg Trojan, Christoph Sarrazin, Wulf O. Böcher, Ulrich Spengler, Hermann E. Wasmuth, Jurrien G.P.
Robert S. O'Shea, Srinivasan Dasarathy, Arthur J. McCullough, Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology – 23 December 2009
Lauren N. Bell, Janice L. Theodorakis, Raj Vuppalanchi, Romil Saxena, Kerry G. Bemis, Mu Wang, Naga Chalasani – 23 December 2009 – Nonalcoholic fatty liver disease (NAFLD), ranging from relatively benign simple steatosis to progressive nonalcoholic steatohepatitis (NASH) and fibrosis, is an increasingly common chronic liver disease. Liver biopsy is currently the only reliable tool for staging the subtypes of NAFLD; therefore, noninvasive serum biomarkers for evaluation of liver disease and fibrosis are urgently needed.
Sanjay Y. Bangarulingam, Einar Bjornsson, Felicity Enders, Emily G. Barr Fritcher, Gregory Gores, Kevin C. Halling, Keith D. Lindor – 23 December 2009 – Patients with primary sclerosing cholangitis (PSC) are at increased risk for developing cholangiocarcinoma (CCA). Fluorescence in situ hybridization (FISH) is a cytological test designed to enhance early CCA diagnosis. The long‐term outcome of PSC patients with a positive FISH test (polysomy, trisomy/tetrasomy) are unclear.
G. Ian Gallicano, Lopa Mishra – 23 December 2009
Hanna C. Hermann, Burghard F. Klapp, Gerhard Danzer, Christina Papachristou – 16 December 2009 – Living donor liver transplantation (LDLT) has developed into an important therapeutic option for liver diseases. For living donor kidney transplantation (LDKT), gender‐specific differences have been observed among both donors (two‐thirds being women and one‐third being men) and recipients (two‐thirds being men and one‐third being women). The aim of this study was to determine whether there is a gender disparity for LDLT.
Guodong Xu, Linyan Wang, Wei Chen, Fei Xue, Xueli Bai, Liang Liang, Xuning Shen, Mangli Zhang, Dajing Xia, Tingbo Liang – 16 December 2009 – Acute graft‐versus‐host disease (aGVHD) is a serious complication of liver transplantation (LTx); it occurs in 1% to 2% of liver allograft recipients. The condition has a poor prognosis and poses major diagnostic and therapeutic challenges. A rat model of aGVHD after LTx has been developed, and a relative decrease in regulatory T (Treg) cells has been shown to be associated with this model.
Kanthi Yalamanchili, Sherif Saadeh, Göran B. Klintmalm, Linda W. Jennings, Gary L. Davis – 16 December 2009 – Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty‐two patients underwent primary liver transplantation for chronic liver disease between 1986 and 2004. Serial liver biopsy samples were assessed for steatosis and fibrosis. Two hundred fifty‐seven patients (12%) had a pretransplant diagnosis of cryptogenic cirrhosis (239) or NASH (18).